bobbybobby
FeatureMarketsStocks

Cencora

COR

$264.75

-0.53%

Cencora, Inc. is a leading pharmaceutical wholesaler operating in the healthcare sector, specifically within the medical distribution industry. The company's core business involves sourcing and distributing branded, generic, and specialty pharmaceutical products to a vast network of pharmacies, hospital networks, and healthcare providers. As one of the three dominant players in the US pharmaceutical wholesale market, alongside McKesson and Cardinal Health, Cencora holds a significant share of an industry characterized by high barriers to entry and scale-driven economics. The current investor narrative is dominated by the stock's recent sharp decline and heightened volatility, which has sparked debate over whether this represents a structural breakdown in the company's stable, defensive business model or a severe but temporary market overreaction, potentially creating a value opportunity given its entrenched market position.…

Should I buy COR
Bobby Quantitative Model
May 20, 2026

COR

Cencora

$264.75

-0.53%
May 20, 2026
Bobby Quantitative Model
Cencora, Inc. is a leading pharmaceutical wholesaler operating in the healthcare sector, specifically within the medical distribution industry. The company's core business involves sourcing and distributing branded, generic, and specialty pharmaceutical products to a vast network of pharmacies, hospital networks, and healthcare providers. As one of the three dominant players in the US pharmaceutical wholesale market, alongside McKesson and Cardinal Health, Cencora holds a significant share of an industry characterized by high barriers to entry and scale-driven economics. The current investor narrative is dominated by the stock's recent sharp decline and heightened volatility, which has sparked debate over whether this represents a structural breakdown in the company's stable, defensive business model or a severe but temporary market overreaction, potentially creating a value opportunity given its entrenched market position.
Should I buy COR

People also watch

McKesson Corporation

McKesson Corporation

MCK

Analysis
Cardinal Health

Cardinal Health

CAH

Analysis
Henry Schein

Henry Schein

HSIC

Analysis
Prestige Consumer Healthcare Inc.

Prestige Consumer Healthcare Inc.

PBH

Analysis
Eli Lilly and Company

Eli Lilly and Company

LLY

Analysis

COR 12-Month Price Forecast

Historical Price
Current Price $264.75
Average Target $264.75
High Target $304.4625
Low Target $225.0375

Wall Street consensus

Most Wall Street analysts maintain a constructive view on Cencora's 12-month outlook, with a consensus price target around $344.18 and implied upside of +30.0% versus the current price.

Average Target

$344.18

8 analysts

Implied Upside

+30.0%

vs. current price

Analyst Count

8

covering this stock

Price Range

$212 - $344

Analyst target range

Buy
2 (25%)
Hold
4 (50%)
Sell
2 (25%)

Analyst coverage for COR is limited, with only 5 analysts providing estimates, indicating this large-cap stock may have subdued institutional interest relative to its size. The consensus sentiment, inferred from recent institutional ratings, is bullish, with firms like Barclays, Wells Fargo, JP Morgan, and Morgan Stanley maintaining or upgrading to Overweight/Outperform ratings in early 2026. An average target price cannot be calculated from the provided data, but the recent upgrades (e.g., Morgan Stanley to Overweight, Jefferies to Buy) suggest a positive shift in analyst sentiment. The lack of a quantified consensus target and upside/downside calculation is a notable data gap. The target range is also not specified in the data, but the recent analyst actions imply a belief that the current price dislocation is overdone. A pattern of reaffirmations and upgrades following the stock's decline in Q1 2026 suggests analysts see fundamental value at these levels. However, the limited number of analysts and the absence of a clear target spread introduces uncertainty; typically, such a situation can lead to higher volatility and less efficient price discovery as the market grapples with a lack of clear consensus benchmarks.

Drowning in data?

Find the real signal!

Chat Now

Drowning in data?

Find the real signal!

Chat Now

COR Technical Analysis

The prevailing price trend for COR is a pronounced and sustained downtrend, with the stock down 28.80% over the last six months and 9.88% over the past year. As of the latest close at $257.71, the stock is trading just 5.3% above its 52-week low of $244.82, positioning it at a mere 13% of its 52-week range ($244.82 to $377.54). This proximity to multi-year lows signals extreme bearish sentiment and suggests the stock is deeply oversold, though it also raises the risk of a 'falling knife' scenario where the downtrend continues. Recent momentum has been severely negative and is accelerating the longer-term decline; the stock is down 28.58% over the last three months and a staggering 18.85% over the past month, indicating intense selling pressure that has overwhelmed any prior support levels. This sharp deceleration conflicts with the broader market, as evidenced by a -36.99 relative strength reading versus the SPY over three months, highlighting severe underperformance. Key technical support is firmly established at the 52-week low of $244.82, while resistance lies far above near the 52-week high of $377.54. A breakdown below the $245 support level would signal a continuation of the bearish trend, whereas a recovery above it could indicate a potential stabilization. The stock's beta of 0.645 suggests it is 35.5% less volatile than the market, which makes its recent extreme drawdown of -32.56% particularly anomalous and points to a significant, company-specific or sector-specific shock.

Beta

0.65

0.65x market volatility

Max Drawdown

-32.6%

Largest decline past year

52-Week Range

$245-$378

Price range past year

Annual Return

-9.6%

Cumulative gain past year

PeriodCOR ReturnS&P 500
1m-18.0%+4.6%
3m-26.3%+8.3%
6m-27.6%+12.5%
1y-9.6%+25.0%
ytd-21.9%+8.7%

Bobby - Your AI Investment Partner

Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions

Try Now

Bobby - Your AI Investment Partner

Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions

Try Now

COR Fundamental Analysis

Cencora's revenue trajectory shows consistent growth, with the most recent quarterly revenue for Q1 2026 reaching $85.93 billion, representing a 5.45% year-over-year increase. This growth is part of a multi-quarter trend of steady expansion, as revenue has climbed from $68.41 billion in Q2 2024 to the current level. The company's profitability is stable but operates on razor-thin margins typical of the distribution industry; net income for the latest quarter was $559.65 million, translating to a net margin of just 0.65%. Gross margin was 3.27% for the quarter, and while this is low, it has shown slight improvement from 2.78% a year prior. The company is consistently profitable on a net income basis, though quarterly results can be volatile due to large one-time items, as seen in the net loss of -$339.70 million in Q4 2025. The balance sheet and cash flow picture is mixed, revealing the capital-intensive nature of the wholesale business. The company carries a high degree of financial leverage, with a debt-to-equity ratio of 7.13. However, it generates substantial cash flow, with trailing twelve-month free cash flow of $3.61 billion. The current ratio of 0.90 indicates potential liquidity strain in covering short-term obligations, but a return on equity of 103.06% (though skewed by low equity) demonstrates efficient use of shareholder capital. The key concern is the negative operating cash flow of -$2.31 billion in the latest quarter, which was driven by a large $3.40 billion negative change in working capital, suggesting a significant inventory or receivables build that may normalize.

Quarterly Revenue

$85.9B

2025-12

Revenue YoY Growth

+0.05%

YoY Comparison

Gross Margin

+0.03%

Latest Quarter

Free Cash Flow

$3.6B

Last 12 Months

Revenue & Net Income Trends (2 Years)

Revenue Breakdown

Animal Health
Other Segments

Open an Account, get $2 TSLA now!

Open Account Now

Open an Account, get $2 TSLA now!

Open Account Now

Valuation Analysis: Is COR Overvalued?

Given that Net Income is positive ($559.65 million in the latest quarter), the primary valuation metric selected is the Price-to-Earnings (PE) ratio. The trailing PE ratio stands at 38.98x, while the forward PE is significantly lower at 13.02x. This substantial gap implies the market expects a sharp recovery in earnings, aligning with analyst EPS estimates averaging $30.74 for the coming period. Compared to sector averages, Cencora's valuation presents a complex picture; its Price-to-Sales ratio of 0.19x and EV-to-Sales of 0.19x are extremely low, reflecting the low-margin, high-volume business model. The trailing PE of 38.98x is elevated, but the forward multiple of 13.02x suggests a more reasonable earnings-based valuation if projected profits materialize. In historical context, the current trailing PE of 38.98x is above the stock's own recent historical range observed in the provided data, where it has fluctuated between negative values and the 20s. Trading near the higher end of its own historical PE band suggests the market, despite the price crash, may still be pricing in relatively optimistic expectations for a earnings rebound, or that the recent earnings are anomalously low. The low PS ratio of 0.19x, however, is near the bottom of its historical range, indicating the market is assigning a deeply discounted multiple to its sales, which could signal a value opportunity if the core revenue stream remains intact.

PE

39.0x

Latest Quarter

vs. Historical

Low-End

5-Year PE Range -45x~3303x

vs. Industry Avg

N/A

Industry PE ~N/A*

EV/EBITDA

17.9x

Enterprise Value Multiple

People also watch

McKesson Corporation

McKesson Corporation

MCK

Analysis
Cardinal Health

Cardinal Health

CAH

Analysis
Henry Schein

Henry Schein

HSIC

Analysis
Prestige Consumer Healthcare Inc.

Prestige Consumer Healthcare Inc.

PBH

Analysis
Eli Lilly and Company

Eli Lilly and Company

LLY

Analysis

Product

Partner

Markets

Stocks

© 2026 Flow AI Limited. All Rights Reserved.

Bobby, the world's first financial AI Agent, is developed by Flow AI, an AI-driven company. Flow AI is dedicated to providing global investors with AI-powered financial services across multiple markets.

Bobby
Bobby AI
RockFlow Platform
Stock Event
Macro Event
Industry Event
NVDA
AAPL
MSFT
AMZN
GOOG
META
TSLA
Privacy Policy
Terms of Use